Germany: Inescapable trap for German parts of European patents not inescapable

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Germany: Inescapable trap for German parts of European patents not inescapable

Contrary to the very strict approach at the EPO in the situation in opposition proceedings referred to as the inescapable trap (where the patentee is squeezed between Article 123(2) and Article 123(3) EPC), which almost exclusively leads to the revocation of a European patent, Germany's Federal Supreme Court (BGH) has established a more liberal practice of dealing with such a situation for national German patents (see in particular the BGH's decision Xa ZB 14/09 Winkelmesseinrichtung).

In Managing IP's edition of October 2014, we reported on decision 4 Ni 34/12 (EP) Fettsaugeabrichtung by Germany's Federal Patent Court (BPatG). In this decision, the BPatG clarified that the above-mentioned case law established for national German patents does not apply to German parts of European patents. The decision could be interpreted such that this opens up a further opportunity for a third party who missed the nine-month opposition deadline in Europe to attack the German part of a European patent in nullity proceedings.

The above no longer applies in view a recent decision by the BGH, Germany's highest instance in patent matters. Although this decision by the BGH (X ZR 161/12 Wundbehandlungsvorrichtung) is not related to the above-mentioned BPatG-decision, the BGH explicitly referred to Fettsaugeabrichtung and took the opposite view of the BPatG. Thus, also the German parts of European patents may be maintained in German nullity proceedings according to the practice established for national German patents.

The BGH based its decision inter alia on Article II § 6 IntPatÜbkG. According to this Article, the nullity grounds for the German part of a European patent are listed in Article 138 EPC. While the BGH acknowledged that Article 138 EPC lists the grounds in an exclusive manner, the BGH went on to say that it is nevertheless possible for a national court to desist from declaring a patent null even if such a ground is present. The BGH further referred to Article 14 GG and stated that the constitutional protection of property including the right on a patent must be protected against unnecessary sovereign intervention. It seems that the BGH balanced this against the very strict inescapable trap approach in EPO practice.

Ledl_Andreas

Andreas Ledl


Maiwald Patentanwalts GmbHElisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

The firm reveals how its litigation strategies informed the arguments that took Masimo’s judgment past $818 million
The firm was rebuilding its IP practice through a string of patent hires and a Texas expansion, but its dissolution has put the newly built talent back into the market
AI can exploit longstanding gaps in copyright protection at remarkable speed, but EU law still provides tools to fight back, says Simon Hembt at Bird & Bird
The firm has tapped a local patent trio to establish a foothold in the market and broaden its national presence
New Asia-Pacific IP head Jonathan Chu is eyeing opportunities arising from Chinese technology licensing, overseas enforcement and increasingly IP-heavy cross-border deals
Europe’s largest intellectual property convention and trade fair is back: IP Service World 2026 takes place in Munich from November 23–25 – the 16th edition, with 1,400-plus attendees from 55-plus nations, 100-plus speakers, and 100-plus exhibitors. Three days. Two focused areas. One IP marketplace.
Mehmet Gün and Uğur Aktekin discuss four decades of change in Türkiye’s legal market, the firm’s commitment to independence and the challenge of building an institution that can outlast its founders
Boehringer Ingelheim has instructed a team from Kirkland, while Teva is being represented by Pinsent Masons
The Delhi High Court’s latest directions offer an opportunity to move beyond remedies against bad-faith registrations and address how suspicious applications are identified in the first place, says Fatima Baig at Lexlinc
Camilla Hamrin describes how the acquisition by Acapo Onsagers will impact Bergenstråhle’s trademark practice – and reflects on changes she has seen over 30 years in IP
Gift this article